Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $82.7M | $3.03M | $1.38M | $25.5M | $10.0M | $15.4M |
| Revenue growth | — | — | -96.3% | -54.4% | 1749.8% | -60.8% | 53.4% |
| Operating income | -$84.0M | -$55.8M | -$365M | -$299M | -$373M | -$372M | -$303M |
| Operating margin | — | -67.5% | -12040.2% | -21670.9% | -1460.1% | -3722.1% | -1971.6% |
| Net income | -$75.3M | -$52.4M | -$364M | -$291M | -$342M | -$338M | -$276M |
| Net margin | — | -63.4% | -12012.9% | -21036.1% | -1338.7% | -3374.7% | -1800.6% |
| EPS (diluted) | -$21.82 | -$5.40 | -$3.82 | -$2.59 | -$2.79 | -$2.36 | -$1.61 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$66.1M | -$102M | -$74.4M | -$229M | -$300M | -$249M | -$235M |
| Capital expenditures | $8.00M | $1.93M | $3.47M | $9.06M | $4.13M | $2.02M | $410K |
| Free cash flow | -$74.1M | -$104M | -$77.9M | -$239M | -$304M | -$251M | -$236M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $42.0M | $448M | $280M | $152M | $144M | $124M | $84.0M |
| Total assets | $393M | $800M | $1.01B | $1.10B | $844M | $871M | $621M |
| Total liabilities | $35.7M | $36.5M | $111M | $150M | $92.0M | $93.5M | $54.3M |
| Shareholders' equity | -$180M | $763M | $898M | $950M | $752M | $778M | $567M |
| Retained earnings | -$189M | -$404M | -$768M | -$1.06B | -$1.40B | -$1.74B | -$2.01B |
| Shares (wtd avg diluted) | 4.04M | 42.6M | 95.1M | 112M | 123M | 143M | 172M |
Every figure is extracted from Relay Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.